(AKTX) Akari Therapeutics - Ratings and Ratios

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, specializes in developing innovative therapies for autoimmune and inflammatory diseases. Its lead product candidate, nomacopan, is a second-generation complement inhibitor designed to target both C5 and LTB4, addressing inflammatory and prothrombotic activities with a dual mechanism of action. The company is also advancing PASylated-nomacopan, a next-generation variant in preclinical development for geographic atrophy secondary to dry age-related macular degeneration, offering potential benefits in stability and half-life. Additionally, Akari is conducting a Phase 3 trial for hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) in pediatric patients, leveraging nomacopans unique mechanism to address this severe and often fatal condition.

Ticker Symbol: AKTX is listed on the NASDAQ exchange, representing common stock in the Pharmaceuticals sector. The company is headquartered in Boston, Massachusetts, and can be found online at https://www.akaritx.com.

Average Volume 20d: 27,836 Last Price: 0.93 SMA 20: 1.01 SMA 50: 1.12 SMA 200: 2.31 ATR: 0.12

Market Cap: 30.35M USD P/E: 0.00 P/E Forward: 0.00 P/B: 3.07 P/S: 0.00 RoE: 291.66

3-Month Forecast: Based on the provided data, AKTX may face resistance at the SMA 20 level of 1.01. If the stock fails to break above this level, it could continue its downward trend, potentially testing lower support levels. The relatively low ATR of 0.12 suggests limited volatility, which may result in a narrow trading range. On the fundamental side, the high P/B ratio of 3.07 indicates that the market expects significant growth, though this may be tempered by the small market capitalization of 30.35M USD. The RoE of 291.66 suggests high efficiency in generating profits with equity, which could attract investors despite the current price trends.